Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 modulate unspecific cellular immune response in healthy adults
- 2007-04-18
- European Journal of Clinical Nutrition 62(5)
- A. Klein
- U. Friedrich
- Heinz Vogelsang
- Gerhard Jahreis
- PubMed: 17440520
- DOI: 10.1038/sj.ejcn.1602761
Abstract
Objective: It was determined whether a combination of Lactobacillus acidophilus (L. acidophilus) 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 (B. lactis 420) affect the faecal microbiota as well as immunological parameters and blood lipids in healthy adults.
Design: A placebo-controlled, double-blinded, randomized crossover trial was conducted.
Subjects: Twenty-six healthy volunteers (mean age 25 years) were recruited by advertising in academical buildings. All of them completed the study.
Methods: After 3-week run-in period, half of the volunteers consumed 300 g/day of yoghurt supplement containing probiotic strains L. acidophilus 74-2 and B. lactis 420, and the other half received the placebo product for a period of 5 weeks. The two groups were crossed during the following 5-week period. Blood and faecal samples were collected at the end of each period. The faecal content of probiotic bacteria, faecal short-chain fatty acids (SCFA), serum lipids and plasma immune system biomarkers were evaluated.
Results: Faecal proportions of L. acidophilus and of B. lactis increased significantly from 0.02 to 0.19 and 0.4 to 1.4% (P<0.05), respectively. Percentages of granulocytes and monocytes showing phagocytic activity were significantly elevated from 92 to 95% during probiotic intervention, whereas their oxidative burst activity and specific immune parameters remained unaffected. Fecal SCFA and serum cholesterol levels were not influenced by the probiotics. However, serum concentrations of triacylglyceroles decreased significantly by 11.6% (P<0.05) in the probiotic supplementation period.
Conclusions: L. acidophilus and B. lactis were recovered in faeces in significantly elevated numbers after supplementation. They are able to modulate unspecific cellular immune response indicated by the increased phagocytic activity.
Research Insights
| Supplement | Health Outcome | Effect Type | Effect Size |
|---|---|---|---|
| Bifidobacterium animalis subsp. lactis B420 | Increased Fecal Probiotic Bacteria | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis B420 | Increased PMN Cell Phagocytic Capacity | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis B420 | Reduced Serum Triacylglycerols | Beneficial | Moderate |
| Bifidobacterium lactis | Increased Fecal Proportion of Lactobacillus acidophilus | Neutral | Moderate |
| Bifidobacterium lactis | Increased Proportion of Fecal Bifidobacterium lactis | Neutral | Moderate |
| Bifidobacterium lactis | Reduced Serum Triacylglycerols | Beneficial | Moderate |
| Bifidobacterium lactis HA-194 | Increased PMN Cell Phagocytic Capacity | Beneficial | Moderate |
| Bifidobacterium lactis HA-194 | Reduced Serum Triacylglycerols | Beneficial | Moderate |
| Bifidobacterium lactis MAK16B42L | Increased PMN Cell Phagocytic Capacity | Beneficial | Moderate |
| Bifidobacterium lactis MAK16B42L | Reduced Serum Triacylglycerols | Beneficial | Moderate |
| Lactobacillus acidophilus | Increased PMN Cell Phagocytic Capacity | Beneficial | Moderate |
| Lactobacillus acidophilus | Reduced Serum Triglyceride Levels | Beneficial | Moderate |
| Lactobacillus acidophilus HA-122 | Increased PMN Cell Phagocytic Capacity | Beneficial | Moderate |
| Lactobacillus acidophilus HA-122 | Reduced Serum Triglycerides | Beneficial | Moderate |
| Lactobacillus acidophilus L-92 | Increased Fecal Probiotic Bacteria | Beneficial | Moderate |
| Lactobacillus acidophilus L-92 | Increased PMN Cell Phagocytic Capacity | Beneficial | Moderate |
| Lactobacillus acidophilus L-92 | Reduced Serum Triacylglycerols | Beneficial | Moderate |
| Lactobacillus acidophilus NCIMB 30333 | Increased PMN Cell Phagocytic Capacity | Beneficial | Moderate |
| Lactobacillus acidophilus NCIMB 30333 | Reduced Serum Triacylglycerols | Beneficial | Moderate |
| Lactobacillus acidophilus R0418 | Increased Fecal Probiotic Bacteria | Beneficial | Moderate |
| Lactobacillus acidophilus R0418 | Increased PMN Cell Phagocytic Capacity | Beneficial | Moderate |
| Lactobacillus acidophilus R0418 | Reduced Serum Triglyceride Levels | Beneficial | Moderate |
| Lactobacillus acidophilus SD-5212 | Improved Phagocytic Activity | Beneficial | Small |
| Lactobacillus acidophilus SD-5212 | Increased Fecal Probiotic Bacteria | Beneficial | Moderate |
| Lactobacillus acidophilus SD-5212 | Reduced Serum Triglycerides | Beneficial | Moderate |
| Lactobacillus acidophilus UALa01 | Increased PMN Cell Phagocytic Capacity | Beneficial | Moderate |
| Lactobacillus acidophilus UALa01 | Reduced Serum Triacylglycerols | Beneficial | Moderate |
| Lactobacillus lactis LI-23 | Increased PMN Cell Phagocytic Capacity | Beneficial | Moderate |
| Lactobacillus lactis LI-23 | Reduced Serum Triacylglycerols | Beneficial | Moderate |